MRI Guided Focal Laser Ablation of Prostate Cancer

This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean

Trial Details

NCT ID
NCT03650595
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • The TRANBERGCLS|Thermal Therapy
Locations (sample)
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Men 40-80 years of age
  • Histologically proven low-intermediate risk prostate carcinoma; (Gleason score ≤ 7, primary grade ≤ 4;)
  • Prostate cancer clinical stage T1c and T2
  • MR site suspicious for cancer or cancer mapped to one lobe of the prostate using the 3D hybrid TRUS device

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →